Effects of ACE inhibitors on skeletal muscle

Current Pharmaceutical Design

Volumn 12, Issue 16, 2006, Pages 2057-2064

  Onder, Graziano ^a   Della Vedova, Cecilia ^b   Pahor, Marco ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; Disability; Older adults; Sarcopenia; Skeletal muscle

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGING; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETIC NEUROPATHY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME INHIBITION; EXERCISE; FUNCTIONAL ASSESSMENT; GENETIC ANALYSIS; GENOTYPE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; MOTOR PERFORMANCE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE FUNCTION; MUSCLE STRENGTH; NEUROTRANSMISSION; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; PHYSICAL DISABILITY; PRIORITY JOURNAL; SKELETAL MUSCLE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; HUMANS; MUSCLE FIBERS; MUSCLE, SKELETAL; MUSCULAR DISEASES; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC;

EID: 33744721759     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777442137     Document Type: Article

References (86)

1. Garg R, Yusuf F. Overview of randomized clinical trial of Angiotensin converting enzyme on mortality and morbidity in patients with congestive heart failure. Collaborative group on ACE Inhibitor. JAMA 1995; 273: 1450-1458.
2. Gambassi G, Lapane KL, Sgadari A, Carbonin P, Gatsonis C, Lipsitz LA, et al. Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Arch Intern Med 2000; 160: 53-60.
3. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
4. Tatti P, Pahor M, Byington RP, DiMauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
5. Estacio RO, Jeffers BW, Hiatt WR, Biggi SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
6. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
7. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000; 23: 888-892.
8. Parmley WW. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am J Med 1998; 105: 27S-31S.
9. Savo A, Maiorano P, Onder G, Bernabei R. Pharmacoepidemiology and disability in older adults: can medications slow the age-related decline in physical function? Expert Opin Pharmacother 2004; 5: 407-13.
10. Jones A, Woods DR. Skeletal muscle RAS and exercise performance. Int J Biochem Cell Biol 2003; 35: 855-66.
11. Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PHM, Williamson JD, Carter C, Di Bari M, Guralnik JM, Pahor M. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002; 359: 926-30.
12. Di Bari M, van de Poll-Franse LV, Onder G, Kritchevsky SB, Newman A, Harris TB, et al. the Health, Aging and Body Composition Study. Antihypertensive medications and differences in muscle mass in older persons. J Am Geriatr Soc 2004; 52: 961-6.
13. Erdos EG. Angiotensin I converting enzyme. Circ Res 1975; 36: 247-55.
14. Reneland R, Lithell H. Angiotensin-converting enzyme in human skeletal muscle. A simple in vitro assay of activity in needle biopsy specimens. Scand J Clin Lab Invest 1994; 54: 105-11.
15. Schaufelberger M, Drexler H, Schieffer E, Swedberg K. Angiotensin-converting enzyme gene expression in skeletal muscle in patients with chronic heart failure. J Card Fail 1998; 4: 185-91.
16. Danser AH, Koning MM, Admiraal PJ, Sassen LM, Derkx FH, Verdouw PD, et al. Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol 1992; 263: H429-37.
17. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995; 92: 1387-1388.
18. Montgomery H, Clarkson P, Barnard M, Bell J, Brynes A, Dollery C, et al. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet 1999; 353: 541-5.
19. Williams AG, Rayson MP, Jubb M, World M, Woods DR, Hayward M, et al. The ACE gene and muscle performance. Nature 2000; 403: 614.
20. Gayagay G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS, et al. Elite endurance athletes and the ACE I allele - the role of genes in athletic performance. Hum Genet 1998; 103: 48-50.
21. Montgomery HE, Marshall R, Hemingway H, Myerson S, Clarkson P, Dollery C, et al. Human gene for physical performance. Nature 1998; 393: 221-2.
22. Woods D, Hickman M, Jamshidi Y, Brull D, Vassiliou V, Jones A, et al. Elite swimmers and the D allele of the ACE I/D polymorphism. Hum Genet 2001; 108: 230-2.
23. Myerson S, Hemingway H, Budget R, Martin J, Humphries S, Montgomery H. Human angiotensin I-converting enzyme gene and endurance performance. J Appl Physiol 1999; 87: 1313-6.
24. Nazarov IB, Woods DR, Montgomery HE, Shneider OV, Kazakov VI, Tomilin NV, et al. The angiotensin converting enzyme I/D polymorphism in Russian athletes. Eur J Hum Genet 2001; 9: 797-801.
25. Zhang B, Tanaka H, Shono N, Miura S, Kiyonaga A, Shindo M, et al. The I allele of the angiotensin-converting enzyme gene is associated with an increased percentage of slow-twitch type I fibers in human skeletal muscle. Clin Genet 2003; 63: 139-44.
26. Rankinen T, Wolfarth B, Simoneau JA, Maier-Lenz D, Rauramaa R, Rivera MA, et al. No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status. J Appl Physiol 2000; 88: 1571-5.
27. Taylor RR, Mamotte CD, Fallon K, van Bockxmeer FM. Elite athletes and the gene for angiotensin-converting enzyme. J Appl Physiol 1999; 87: 1035-7.
28. Frederiksen H, Bathum L, Worm C, Christensen K, Puggaard L. ACE genotype and physical training effects: a randomized study among elderly Danes. Aging Clin Exp Res 2003; 15: 284-91.
29. Frederiksen H, Gaist D, Bathum L, Andersen K, McGue M, Vaupel JW, et al. Angiotensin I-converting enzyme (ACE) gene polymorphism in relation to physical performance, cognition and survival - a follow-up study of elderly Danish twins. Ann Epidemiol 2003; 13: 57-65.
30. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H, et al. Angiotensin-converting enzyme genotype affects the response of human skeletal muscle to functional overload. Exp Physiol 2000; 85: 575-9.
31. Kritchevsky SB, Nicklas BJ, Visser M, Simonsick EM, Newman AB, Harris TB, et al. Angiotensin Converting Enzyme Insertion/Deletion genotype, exercise and physical decline: Evidence of a gene-environment interaction. J Am Geriatr Soc 2004; 52: A29.
32. Woods D, Onambele G, Woledge R, Skelton D, Bruce S, Humphries SE, et al. Angiotensin-I converting enzyme genotype-dependent benefit from hormone replacement therapy in isometric muscle strength and bone mineral density. J Clin Endocrinol Metab 2001; 86: 2200-4.
33. Braun A, Kammerer S, Maier E, Bohme E, Roscher AA. Polymorphisms in the gene for the human B2-bradykinin receptor. New tools in assessing a genetic risk for bradykinin-associated diseases. Immunopharmacology 1996; 33: 32-5.
34. Williams AG, Dhamrait SS, Wootton PT, Day SH, Hawe E, Payne JR, et al. Bradykinin receptor gene variant and human physical performance. J Appl Physiol 2004; 96: 938-42.
35. Vescovo G, Dalla Libera L, Serafini F, Leprotti C, Facchin L, Volterrani M, et al. Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation 1998; 98: 1742-9.
36. Rattigan S, Dora KA, Tong AC, Clark MG. Perfused skeletal muscle contraction and metabolism improved by angiotensin II-mediated vasoconstriction. Am J Physiol 1996; 271: E96-103.
37. Schaufelberger M, Andersson G, Eriksson BO, Grimby G, Held P, Swedberg K. Skeletal muscle changes in patients with chronic heart failure before and after treatment with enalapril. Eur Heart J 1996; 17: 1678-85.
38. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93: 2379-86.
39. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a sub-group of patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 819-24.
40. Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999; 20: 683-93.
41. Haslett P, Hempstead M, Seidman C, Diakun J, Vasquez D, Freedman VH, et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 1997; 13: 1047-54.
42. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci 2002; 57: M326-32.
43. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 1999; 84: 695-703.
44. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kohler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 1623-9
45. Brull DJ, Sanders J, Rumley A, Lowe GD, Humphries SE, Montgomery HE. Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart 2002; 87: 252-5.
46. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-8.
47. Chen R, Iwai M, Wu L, Suzuki J, Min LJ, Shiuchi T, et al. Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension 2003; 42: 542-7.
48. Moldawer LL, Copeland EM 3rd. Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer 1997; 79: 1828-39.
49. Levens NR. Local control of jejunal absorption by the reninangiotensin system. J Cardiovasc Pharmacol 1986; 8(Suppl 10): S17-22.
50. Bunnemann B, Fuxe K, Ganten D. The brain renin-angiotensin system: localization and general significance. J Cardiovasc Pharmacol 1992; 19: S51-62.
51. Carter CS, Cesari M, Ambrosius WT, Hu N, Diz D, Oden S, et al. Angiotensin-converting enzyme inhibition, body composition, and physical performance in aged rats. J Gerontol A Biol Sci Med Sci 2004; 59: 416-23.
52. Wali FA. Effect of angiotensin II on mechanical and electrical responses of frog, chick and rat skeletal muscle. Arch Int Pharmacodyn Ther 1986; 282: 314-27.
53. Seyedi N, Win T, Lander HM, Levi R. Bradykinin B2-receptor activation augments norepinephrine exocytosis from cardiac sympathetic nerve endings. Mediation by autocrine/paracrine mechanisms. Circ Res 1997; 81: 774-84.
54. Schwieler JH, Hjemdahl P. Influence of angiotensin-converting enzyme inhibition on sympathetic neurotransmission: possible roles of bradykinin and prostaglandins. J Cardiovasc Pharmacol 1992; 20(Suppl 9): S39-46.
55. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
56. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069-75.
57. Takeshita S, Tomiyama H, Yokoyama N, Kawamura Y, Furukawa T, Ishigai Y, et al. Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats. Cardiovasc Res 2001; 52: 314-20.
58. Fabre JE, Rivard A, Magner M, Silver M, Isner JM. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999; 99: 3043-9.
59. Gohlke P, Kuwer I, Schnell A, Amann K, Mall G, Unger T. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1997; 29: 478-82.
60. Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Battegay EJ. Hypertension and angiogenesis. Curr Pharm Des 2003; 9: 1733-44.
61. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 2001; 89: 678-83.
62. Zimmermann R, Kastens J, Linz W, Wiemer G, Scholkens BA, Schaper J. Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats. J Mol Cell Cardiol 1999; 31: 1447-56.
63. Henriksen EJ, Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 2003; 196: 171-9.
64. Cahova M, Vavrinkova H, Tutterova M, Meschisvilli E, Kazdova L. Captopril enhanced insulin-stimulated glycogen synthesis in skeletal muscle but not fatty acid synthesis in adipose tissue of hereditary hypertriglyceridemic rats. Metabolism 2003; 52: 1406-12.
65. Short KR, Nair KS. Does aging adversely affect muscle mitochondrial function? Exerc Sport Sci Rev 2001; 29: 118-23.
66. Kamel HK, Maas D, Duthie EH Jr. Role of hormones in the pathogenesis and management of sarcopenia. Drugs Aging 2002; 19: 865-77.
67. Cappola AR, Bandeen-Roche K, Wand GS, Volpato S, Fried LP. Association of IGF-I levels with muscle strength and mobility in older women. J Clin Endocrinol Metab 2001; 86: 4139-46.
68. Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafe M, et al. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 2003; 284: E481-7.
69. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 1996; 97: 2509-11.
70. Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE, et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 2001; 142: 1489-96.
71. Ferrucci L, Guralnik JM, Pahor M, Corti MC, Havlik RJ. Hospital diagnoses, Medicare charges and nursing home admissions in the year when older persons become severely disabled. JAMA 1997; 277: 728-734.
72. Fried LP, Guralnik JM. Disability in older adults: evidence regarding significance, etiology, and risk. J Am Geriatr Soc 1997; 45: 92-100.
73. Pahor M, Kritchevsky S. Research hypotheses on muscle wasting, aging, loss of function and disability. J Nutr Health Aging 1998; 2: 97-100.
74. Roubenoff R. The pathophysiology of wasting in the elderly. J Nutr 1999; 129: 256S-259S.
75. Hyatt RH, Whitelaw MN, Bhat A, Scott S, Maxwell JD. Association of muscle strength with functional status of elderly people. Age Ageing, 1990; 19: 330-336.
76. Porter MM, Vandervoort AA, Lexell J. Aging of human muscle: structure, function and adaptability. Scand J Med Sci Sports 1995; 5: 129-42.
77. Dutta C, Hadley EC. The significance of sarcopenia in old age. J Gerontol A Biol Sci Med Sci 1995; 50 Spec No: 1-4.
78. Dutta C. Significance of sarcopenia in the elderly. J Nutr 1997; 127: 992S-993S.
79. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 1997; 278: 1745-8.
80. Onder G, Gambassi G, Landi F, Pedone C, Cesari M, Carbonin PU, et al. Investigators of the GIFA Study (SIGG-ONLUS). Trends in antihypertensive drugs in the elderly: the decline of thiazides. J Hum Hypertens 2001; 15: 291-7.
81. Timpe EM, Amarshi N, Reed PJ. Evaluation of angiotensin-converting enzyme inhibitor use in patients with type 2 diabetes in a state managed care plan. Am J Manag Care 2004; 10: 124-9.
82. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002, 346: 1145-51.
83. Onder G, Pahor M, Gambassi G, Federici A, Savo A, Carbonin P, et al. GIFA Study. Association between ACE inhibitors use and headache caused by nitrates among hypertensive patients: results from the Italian group of pharmacoepidemiology in the elderly (GIFA). Cephalalgia 2003; 23: 901-6.
84. Pahor M, Gambassi G, Carbonin P. Antiarrhythmic effects of ACE inhibitors: a matter of faith or reality? Cardiovasc Res 1994; 28: 173-82.
85. Sekizawa K, Matsui T, Nakagawa T, Nakayama K, Sasaki H. ACE inhibitors and pneumonia. Lancet 1998; 352: 1069.
86. Onder G, Penninx BW, Lapuerta P, Fried LP, Ostir GV, Guralnik JM, et al. Change in physical performance over time in older women: the Women's Health and Aging Study. J Gerontol A Biol Sci Med Sci 2002; 57: M289-93.